{"groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T cells. Prior to dosing, participants had to remain eligible and, prior to dosing, were given lymphodepleting chemotherapy (fludarabine and cyclophosphamide). Six (6) participants were dosed once with a mean total of 50.7 x 10\\^7 TC-510 T cells (mITT population). All subjects completed the interventional phase of the trial.","id":"FG000","title":"Phase 1"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Did not meet eligibility criteria prior to lymphodepletion and dosing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Fourteen (14) participants were screened and subsequently underwent leukapheresis in Phase 1 (Intent-to-Treat population). Six (6) participants received lymphodepleting chemotherapy and were dosed in Phase 1 (modified Intent-to-Treat population).\n\nNo participants were subsequently included in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity."}